Schisandrin B attenuates acetaminophen-induced hepatic injury through heat-shock protein 27 and 70 in mice.
OBJECTIVE
Schisandrin B is an active component isolated from Schisandra chinensis (TurcZ.) Baill. that is widely used as an antihepatotoxic agent. Schisandrin B has significant hepatoprotective effect against chemical and immunological liver injury. This study aimed to investigate the effect of Schisandrin B on the expression of 27- and 70-kDa heat-shock protein (HSP) and its role in protection against acetaminophen-induced liver injury in mice.


METHODS
After the mice were pretreated, Western blot and real-time quantitative polymerase chain reaction were used to detect the protein and gene expression of HSP27 and HSP70, respectively; the liver tissues were subjected to histological evaluation, and alanine aminotransferase and aspartate aminotransferase activities in the serum were measured.


RESULTS
Oral administration of Schisandrin B increased the expression of HSP27 and HSP70 in a time- and dose-dependent manner. The inducing effect of Schisandrin B on HSP27 and HSP70 was also confirmed by real-time quantitative polymerase chain reaction. In the acetaminophen-induced liver injury mouse model, the prior oral administration of Schisandrin B (200 mg/kg) three times in 24 h markedly alleviated liver injury as indicated by the amelioration of histopathological hepatic necrosis and the reduction of alanine aminotransferase and aspartate aminotransferase activities in the serum. However, the earlier actions of Schisandrin B were all suppressed significantly by Quercetin, a known HSP inhibitor.


CONCLUSIONS
The hepatic cytoprotective action of Schisandrin B against acetaminophen-induced liver injury is mediated, at least in part, by the induction of HSP27 and HSP70 in mice.
Department of Pharmacology, Qiqihar Medical University, Qiqihar, China.
Libo
L
Li
Tiran
T
Zhang
Li
L
Zhou
Li
L
Zhou
Guihua
G
Xing
Yuhang
Y
Chen
Yabing
Y
Xin
D000082:Acetaminophen / Q000009:adverse effects*; D000284:Administration, Oral; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000517:prevention & control; D034242:Cyclooctanes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression / Q000187:drug effects*; D055551:HSP27 Heat-Shock Proteins / Q000235:genetics* / Q000378:metabolism*; D018840:HSP70 Heat-Shock Proteins / Q000235:genetics* / Q000378:metabolism*; D017705:Lignans / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008517:Phytotherapy; D011083:Polycyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D032141:Schisandra; D013997:Time Factors
D034242:Cyclooctanes; D055551:HSP27 Heat-Shock Proteins; D018840:HSP70 Heat-Shock Proteins; D017705:Lignans; D011083:Polycyclic Compounds; C015499:schizandrin B; D000082:Acetaminophen
Schisandrin B; acetaminophen; heat-shock protein; liver injury